TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Summary

This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory). TAK-243 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2025-03-12

Primary completion

2026-10-24

Completion

2026-10-24

Outcome

Outcome not reported

Stopped: “Other - Pending amendment addressing dose escalation plan.”

Drugs

Indications